BioSpace News Archive

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today reported its financial results for the full year 2021, its recent business highlights, and a preview of anticipated select milestones in 2022.

Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.

Taro Pharmaceutical Industries Ltd. announced the completion of its acquisition of Alchemee, formerly The Proactiv Company, from Galderma.

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.

Legend Biotech Corporation announced that the U.S. Food and Drug Administration has approved its first product, CARVYKTI™, for the treatment of adults with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group; Andy Schmeltz, Global President, Oncology; and Suneet Varma, Global President, Rare Disease at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. Eastern Standard Time.

City of Hope and Osel Inc. announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 plus immunotherapy medicine nivolumab/ipilimumab significantly improved progression-free survival in patients with metastatic kidney cancer when compared to use of nivolumab/ipilimumab alone.

Actym Therapeutics, a biotechnology company focused on the discovery and development of novel therapies intended to transform the treatment of cancer, and Wacker Biotech announced today that they have signed a contract for the manufacturing of Actym’s lead clinical candidate, ACTM-838, for the treatment of solid tumors.

Lura Health, an innovative medical device company developing the first wearable salivary diagnostic health monitoring system, announced that the National Science Foundation has awarded the company a Phase II Small Business Innovation Research grant.

High adoption of blockchain technology in several hospitals and organizations, and favorable government initiatives are key factors expected to drive global market revenue growth.